Biotech

Engine Capital filed a 13D targeting PDL BioPharm (PDLI) on Wednesday morning, disclosing a 5.28% stake in the Nevada-based healthcare stock. Engine also disclosed it sent a letter to PDLI's board saying the fund "invested in PDLI because of the significant intrinsic value attributable to...

Billionaire Mori Arkin filed a 13D on Aclaris Therapeutics (ACRS), a development stage microcap biotech company with a promising treatment for common warts. Arkin bought the shares through his personal partnership, "The 1999 Company." In the activist filing he disclosed the following trades: Purchase/SaleSharesPriceDate Running ...

Baupost Group activist filings are rare events. Seth Klarman, the renowned value investor who heads Baupost, prefers to take passive stakes in companies. Since 2006, Baupost has filed 352 passive 13G filings, and made only 25 activist 13D filings, according to data from WhaleWisdom.com.

Intra-Cellular Therapies FDA news release on Sept. 10 appeared positive. The FDA informed the company that it will not schedule an Advisory Committee meeting in connection with its review of the company’s new drug application (NDA) for Lumateperone for the treatment of schizophrenia. All good, moving ahead,...

Replicating Baker Brothers holdings, using 13F filings submitted quarterly by the life sciences hedge fund, has been an awesome strategy over the years. But by focusing on the smaller stocks owned by the fund, returns were even better. Baker Bros Advisors LP, with $17.33...

Solid Biosciences' private placement featured investments by an all star list of top biotech institutional investors. Cambridge-based Solid Biosciences (SLDB) trades at 1/3 of its January 2018 IPO value. But based on the A-list biotech investors buying shares in the company's July 26 $60...

Twenty-two minutes after regular market hours closed on July 2, an Orbimed Advisors Form 4 relating to Corvus Pharmaceuticals Inc (CRVS) was posted on the SEC's website. The hedge fund, a 10%+ holder and insider in CRVS, disclosed that between June 27 and July 1 it...

RA Capital Management leads the pack when it comes to health care stock selection. Since 2008, an equal-weight portfolio of the Boston-based hedge fund's top ten 13F positions would have averaged a 37.05% annual return. So, when RA Capital adds to a position, it pays to investigate....

In the investing world, those with superior information usually make the most money. And possibly no group has better information on public companies – and profitably acts on it – than corporate insiders at small-cap biotech and medical technology companies.